By Norbert Sparrow -
10 May, 2012
By Helen Zhang -
8 May, 2012
Johnson & Johnson (China) Investment Ltd. acquired Guangzhou Bioseal Biotech Company, Ltd, earlier this month. Helen Zhang, Associate Editor of China Medical Device Manufacturer (CMDM), interviewed Karen Jiang, Senior Media Affairs Manager, Johnson & Johnson Medical, to learn more about the acquisition.
By Norbert Sparrow -
26 April, 2012
A badly designed package or device can make a person feel even sicker than he or she actually is, or it can give that impression to others around him or her, writes Dan Formosa of Smart Design.
By Norbert Sparrow -
24 April, 2012
Despite historically high unemployment numbers in the United States, a growing number of jobs in the medtech space are going unfilled because of a dearth of talent, according to a report from the World Economic Forum.
By Norbert Sparrow -
21 April, 2012
The new innovation challenge is cost reduction and improving the standard of care, says Paul Fearis, CEO of medical product research firm Clinvue.
By Norbert Sparrow -
17 April, 2012
The LifeTouch Patient Surveillance System is reportedly the first CE-marked Class IIa medical device to be designed for use with cloud-based technology.
By Norbert Sparrow -
16 April, 2012
It's manna for the media, but it's not doing the medtech industry, caregivers or patients any good. I'm talking, of course, about the feud between Medtronic and St. Jude over the number of deaths associated with their defibrillator leads.
By Norbert Sparrow -
10 April, 2012
A researcher at security firm McAfee found a way to scan for and compromise insulin pumps that communicate wirelessly.
By Norbert Sparrow -
9 April, 2012
Consumer Reports may have overreached in its recent evaluation of medical products. An article titled "CR Investigates: Dangerous medical devices" is "dangerous reporting" in the view of MD+DI Editor-in-Chief Heather Thompson.
By Norbert Sparrow -
5 March, 2012
The 2.3% excise tax on medical devices that is scheduled to take effect in the United States in 2013 will stifle innovation and kill startups before they can get off the ground, cautions Josh Makower, MD, and CEO and founder of ExploraMed Development.
